Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 7.1% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares were down 7.1% on Tuesday following insider selling activity. The stock traded as low as $6.07 and last traded at $6.12. Approximately 4,751,581 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 5,863,063 shares. The stock had previously closed at $6.59.

Specifically, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00. Following the transaction, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,647,966. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on RXRX shares. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Jefferies Financial Group lowered their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Finally, KeyCorp cut their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Performance

The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -3.82 and a beta of 0.82. The stock’s 50 day moving average price is $7.00 and its 200 day moving average price is $8.16. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same quarter in the prior year, the business earned ($0.38) EPS. The business’s revenue was up 30.9% compared to the same quarter last year. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RXRX. Mubadala Investment Co PJSC acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $128,041,000. Capstone Investment Advisors LLC acquired a new position in Recursion Pharmaceuticals in the 1st quarter valued at about $161,000. Perceptive Advisors LLC bought a new position in Recursion Pharmaceuticals in the 2nd quarter valued at about $5,769,000. UBS Group AG raised its holdings in Recursion Pharmaceuticals by 101.9% in the 4th quarter. UBS Group AG now owns 691,911 shares of the company’s stock valued at $6,822,000 after acquiring an additional 349,232 shares during the period. Finally, Scientech Research LLC bought a new stake in shares of Recursion Pharmaceuticals during the second quarter worth approximately $1,052,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.